News Archive

Top scientists and physicians from the ABC Science Collaborative have shared insights from North Carolina schools, coupled with a science-based blueprint for all schools to resume full, in-person instruction safely. A new report issued today by the DCRI-led ABC Science Collaborative shows that North Carolina schools were highly successful in preventing the transmission of COVID-19 within school buildings and offers science-based learnings for the nation’s schools to limit COVID-19 spread.

A large pragmatic study in idiopathic pulmonary fibrosis (IPF) found that antimicrobial therapy did not have a statistically significant effect on respiratory hospitalization or death compared with usual care alone.

The late-breaking clinical trial found no difference between the intervention group and the control group when examining an audit and feedback initiative that was hypothesized to improve heart failure care. An effort to improve the quality of heart failure care focused on audit and feedback did not significantly improve either the outcomes of patients with heart failure or the quality of care they received, according to late-breaking clinical trial results presented today at the American College of Cardiology’s 70th annual Scientific Session & Expo.

Late-breaking clinical trial results provide new insight into how to treat patients who are hospitalized with COVID-19 and at risk for blood clots. Findings from the ACTION trial, which was led by the Brazilian Clinical Research Institute in collaboration with DCRI’s Renato Lopes, MD, PhD, were presented by Lopes Sunday at the American College of Cardiology’s 70th annual Scientific Session & Expo. Results were also published after the conference in The Lancet.

Results from a landmark clinical trial that sought to determine the safest and most effective dose of aspirin for patients with existing cardiovascular disease were presented Saturday morning as part of the 70th annual American College of Cardiology Scientific Session & Expo.

The Antibacterial Resistance Leadership Group (ARLG) involves over 100 experts, generating over 155 papers and initiating 55+ studies with 21,000 participants at 130 sites in 12 countries.

More than twice as many patients saw changes in their patient-reported outcome measures compared with their traditional NYHA measures used by clinicians.

The HiLo study seeks to determine the optimal phosphate level for patients with chronic kidney disease.

Over a third of patients with diabetes and heart disease were not taking any of the three therapies proven to prevent major adverse cardiovascular events.

The rate of transmission within schools was found to be much lower than the rate of community spread of the disease.